

Lucian Ionescu
Lucian Ionescu joined UCB in 2006, and since then, has contributed to building the immunology franchise through a track record of strategic and operational leadership roles, in Global Brand Leadership (Cimzia Pre/Launch and Commercial Implementation), Strategic Projects and Early Medicines (Bimzelx Early Development), Medical and Clinical Affairs, Global Corporate, in Europe and the United States. He built twice medical affairs organizations (Global and US), and acted as a global project leader for two launches, in rheumatology Cimzia NR axSpA and dermatology Cimzia PsO. Lucian combines passion for science with translation into patient value. He is versatile in understanding the commercial processes, marketplace dynamics, stakeholders, ecosystems, towards integration and decision-making for value creation holistically.
Lucian is a Medical Doctor (MD), and before joining UCB, has worked as a clinician in Romania, and as a scientist at University of Pennsylvania. Over his 22 yrs of professional career, he published in multiple scientific journals; he holds an MBA from Vlerick Business School, a top-100-business school, and executive degrees from Wharton, MIT, Insead and IMD (Executive Management, Artificial Intelligence and Business Strategy).
Since Sep 2019, Lucian leads the European Immunology Commercial Operations at UCB, and is responsible for evolving the business from one biologic/one therapeutic area to a portfolio of biologics across three therapeutic areas (rheumatology, dermatology, osteoporosis). Passionate about Digital Business Transformation, he and the team aspire to partner internally and externally towards contributing to digitizing and optimizing the health care system, while benefiting patients of innovative medicines across Europe during the next few years.

Navigating the new European S2k guidelines for hidradenitis suppurativa: How will they change your clinical practice?
Prof. Tzellos, Dr Martorell, Dr McGrath and Prof. Jemec detail HS treatment options, the role of imaging and the HCP-patient relationship.

Setting up MDT care in HS: Learning from psoriasis
Establishing a multidisciplinary team to alleviate disease burden and optimise patient outcomes, using the principles of value-based healthcare

Use of imaging in HS management
Transformative role of ultrasound and magnetic resonance imaging in HS management, and how AI-driven technologies may enhance disease characterisation

Evidence-based approach to medical management based on the European guidelines for HS
Latest evidence-based strategies for effective HS medical management including antibiotics and biologic therapy

Informed decisions for effective HS management
Different HS phenotypes and disease severity scores: their role in informing management decisions

The role of surgery in HS management: Optimising patient results
Surgical management of HS, through minor procedures to more complex interventions